Normal healthy subjects
Conditions
Interventions
After injection of 10-50 ml of local anesthesia solution into periumbilical or femoral regions, approximately 10 ml of lipoaspirate is collected using liposucsion cannula. Then DFAT cells are prepared
Sponsors
Nihon University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Participants will be in good health without severe dysfunction of heart, kidney, lung, hematopoiesis. (2) Subjects with preliminary laboratory tests results considered adequate. (3) Individuals who are willing to participate in this study with written informed consent. (4) Subjects who are judged by investigator to be able to undergo liposuction.
Exclusion criteria
Exclusion criteria: (1) Positive for the following laboratory test results: serological test for syphilis, HBs antigen, HCV antibody, and HIV antibody. (2) Current active infection or diagnosed with severe infectious diseases within the last 3 months. (3) Current use of anticoagulation medications that affect bleeding. (4) Subjects with history of drug or alcohol dependence. (5) Current use of systemic steroids or immunosuppressive agents (6) Pregnant woman, lactating mother, or woman who is suspected pregnancy. (7) Any other medical reasons judged by the doctor-in-charge.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Preparation of the good manufacturing practice-compliant production of DFAT cells | — |
Secondary
| Measure | Time frame |
|---|---|
| Therapeutic potential and transplantation safety of DFAT cells will be assessed by animal experiments | — |
Countries
Japan
Contacts
Public ContactTomohiko Kazama
Nihon University School of Medicine Division of Cell Regeneration and Transplantation
Outcome results
None listed